Determining class I human leukocyte antigens on specimens for those patients who have become refractory to platelet transfusions and identify potential disease association
Polymerase Chain Reaction (PCR)/Sequence-Specific Oligonucleotide Probes (SSO)
1DIS
Whole Blood ACD
Container/Tube: Yellow top (ACD solution A or B)
Specimen Volume: 6 mL
Collection Instructions: Send whole blood in original tube. Do not aliquot.
Additional Information: Specimen acceptability is based on extracted DNA concentration and not sample age.
If not ordering electronically, complete, print, and send a Hematopathology/Cytogenetics Test Request (T726) with the specimen.
3 mL
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Whole Blood ACD | Ambient (preferred) | ||
Refrigerated |
Determining class I human leukocyte antigens on specimens for those patients who have become refractory to platelet transfusions and identify potential disease association
Human leukocyte antigens (HLA) are regulators of the immune response. HLA class I typing is used to identify HLA-matched platelets for alloimmunized refractory patients and identify presence of HLA antigens associated with a number of diseases or as drug hypersensitivity markers Class I HLA antigens include A, B, and C loci. This assay is designed to provide low-to-medium resolution for HLA class I typing (A, B, C). Low-to-medium resolution defines the typing at the antigen level (first field). This contrasts with high-resolution typing, which defines typing at the allele (molecular) level (second field or higher).
Not applicable
Interpretation depends on the rationale for ordering the test.
No significant cautionary statements
2. Colinas RJ, Bellisario R, Pass KA: Multiplexed genotyping of beta-globin variants from PCR-amplified newborn blood spot DNA by hybridization with allele-specific oligodeoxynucleotides coupled to an array of fluorescent microspheres. Clin Chem. 2000 Jul:46(7):996-998
3. Kennedy AE, Ozbek U, Dorak MT: What has GWAS done for HLA and disease associations? Int J Immunogenet. 2017 Oct;44(5):195-211. doi: 10.1111/iji.12332
4. Caillat-Zucman S: New insights into the understanding of MHC associations with immune-mediated disorders. HLA. 2017 Jan;89(1):3-13. doi: 10.1111/tan.12947
5. Howell WM: HLA and disease: guilt by association. Int J Immunogenet. 2014 Feb;41(1):1-12. doi: 10.1111/iji.12088
6. Profaizer T, Pole A, Monds C, Delgado JC, Lazar-Molnar E: Clinical utility of next generation sequencing based HLA typing for disease association and pharmacogenetic testing. Hum Immunol. 2020 Jul;81(7):354-360
The reverse sequence-specific oligonucleotide DNA typing method consists of using polymerase chain reaction (PCR) to amplify target DNA with group specific primers. The PCR product is denatured and allowed to rehybridize to complementary DNA probes bound to fluorescently coded microspheres. The mixture is labeled with a fluorescent dye that is able to detect biotinylated protein and nucleic acids. A flow analyzer detects the fluorescent emission on each probe and the reaction pattern is analyzed and interpreted. The assignment of the human leukocyte antigen (HLA) typing is based on the reaction pattern compared to patterns associated with published HLA gene sequences.(Package insert: LABType SSO Typing Test. One Lambda, Inc.; Rev 04, 11/11/2019)
For resolution of an allelic ambiguity or in select cases, the following additional methodologies may be utilized:
-Sequence-based typing by Sanger sequencing(Package insert: SeCore Sequencing and GSSP Kits. One Lambda, Inc; Rev 3, 02/06/2021)
-SBT by sequence-specific primers(Package insert: Olerup SSP HLA typing kits including Taq Polymerase. CareDx; Rev 04, 12/2020)
-SBT by next-generation sequencing(Package inserts: Holotype HLA Kit. Omixon; v3.0.1, 08/16/2019; NGSgo HLA Kit. GenDx; v2, 02/2021)
Monday
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
81372
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
1DIS | HLA-A-B-C DisAssoc Typing LowRes,B | 96629-1 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
1DA02 | ABC DisAssoc Comment | 96625-9 |
1DA03 | A - 1 Equivalent | 13298-5 |
1DA04 | A - 2 Equivalent | 13298-5 |
1DA05 | A - 1 Molecular | 78014-8 |
1DA06 | A - 2 Molecular | 78014-8 |
1DA07 | B - 1 Equivalent | 13299-3 |
1DA08 | B - 2 Equivalent | 13299-3 |
1DA09 | B - 1 Molecular | 78015-5 |
1DA10 | B - 2 Molecular | 78015-5 |
1DA11 | Bw - 1 Equivalent | 96633-3 |
1DA12 | Bw - 2 Equivalent | 96633-3 |
1DA13 | C - 1 Equivalent | 13302-5 |
1DA14 | C - 2 Equivalent | 13302-5 |
1DA15 | C - 1 Molecular | 96636-6 |
1DA16 | C - 2 Molecular | 96636-6 |
LRTMB | Test Method | 85069-3 |
LRTM1 | Test Method | 85069-3 |
Change Type | Effective Date |
---|---|
Test Changes - Method | 2022-03-24 |